Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 552

Dr David R. Spigel - Tennessee Oncology, Nashville, USA

Dr David R. Spigel speaks with ecancer at ESMO 2018 in Munich about results from the ABOUND.sqm study which looked into the therapy of nab-paclitaxel and whether it could be extended into a maintenance setting.

Dr Spigel explains that there was an early stopping point in the study due to an enrolment delay as immunotherapy found its place in the second and first line settings.

He outlines that, up to this point, they found no statistical advantage for the nab-paclitaxel arm over the control arm for progression free survival, although there was suggestion of a benefit when removing those that received immunotherapy.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation